A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC).

Start Date01 Dec 2025

Sponsor / Collaborator

Corcept Therapeutics, Inc.

NCT06906341

/ RecruitingPhase 2

An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)

This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

Start Date11 Apr 2025

Sponsor / Collaborator

Corcept Therapeutics, Inc.

NCT05726292

/ RecruitingPhase 2IIT

A Randomized Phase II Trial of Neoadjuvant Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.

Start Date06 Jan 2025

Sponsor / Collaborator

The University of Chicago

100 Clinical Results associated with Relacorilant

100 Translational Medicine associated with Relacorilant

100 Patents (Medical) associated with Relacorilant

Literatures (Medical) associated with Relacorilant

01 Oct 2025·Med

Targeting the glucocorticoid receptor as a therapeutic strategy for ovarian cancer: The ROSELLA study

Article

Author: Matulonis, Ursula A ; Lantsman, Taliya

The ROSELLA trial tested the combination of intermittently dosed relacorilant, a novel glucocorticoid receptor antagonist, plus nab-paclitaxel versus nab-paclitaxel alone in recurrent platinum-resistant ovarian cancer (PROC).¹ Interim results showed, for the combination, a 1-month improvement in median progression-free survival (PFS) and overall survival improvement versus single-agent nab-paclitaxel. Toxicities were higher in the combination arm versus single-agent nab-paclitaxel.

01 Aug 2025·PHYTOMEDICINE

Tanshinone IIA improved psychological stress-induced embryo implantation disorders by inhibiting GC/GR signaling and promoting angiogenesis

Article

Author: Fang, Qunying ; Zong, Lu ; Wang, Jiawei ; Han, Hui ; Zhao, Shiyu ; Shui, Lijun ; Chen, Shengyuan ; Li, Fangfang ; Meng, Ye ; Jin, Qi ; Wu, Limin ; Qiao, Zonghui

BACKGROUND:

The exact mechanism by which psychological stress leads to embryo implantation disorders remains unclear. Studies have shown that psychological stress is associated with elevated levels of glucocorticoids (GC). Successful embryo implantation is closely related to normal endometrial angiogenesis, a key process in the creation of a conducive environment for embryo implantation. Tanshinone IIA (Tan IIA), a compound derived from traditional Chinese medicine, promotes angiogenesis. This study aimed to elucidate how psychological stress impairs embryo implantation and explore the potential therapeutic effects of Tan IIA.

METHODS:

Female mice were randomly divided into seven groups: control, restraint stress, CORT125134 antagonizing glucocorticoid receptor (GR), 7.5, 15, 30 mg/kg Tan IIA, and aspirin. Open-field and elevated plus maze tests were employed to evaluate behavioral changes. The embryo implantation sites were quantified using trypan blue injection. Endometrial GC levels by ELISA, GR expression by RT-qPCR and WB, angiogenesis by HE and IHC, and angiogenic factors (VEGF, ANG2) by IF were measured. JC-1, ATP, p-DRP1^S616, and transmission electron microscopy were used to detect endometrial mitochondrial damage. Oxidative stress was determined through ROS, MDA, catalase, and GPX4 assays, and IF co-staining of CD31 with 4-HNE examined vascular oxidative injury. Endometrial receptivity was evaluated by LIF and integrin αvβ3 expression.

RESULTS:

Psychological stress significantly induced anxiety-like behavior, reduced implantation sites, impaired endometrial angiogenesis, triggered mitochondrial dysfunction and oxidative stress, and compromised endometrial receptivity via GC/GR signaling activation. Administration of Tan IIA effectively alleviated these stress-induced impairments in a dose-dependent manner, primarily by inhibiting GC/GR activation and GR nuclear translocation. Specifically, Tan IIA alleviated anxiety-like behavior, reduced the p-DRP1^S616/DRP1 ratio, restored MMP and ATP production, and attenuated mitochondrial vacuolization and crista disruption. In addition, Tan IIA markedly decreased the levels of ROS, MDA, and CAT, while enhancing the expression of GPX4, VEGF, ANG2, LIF, and integrin αvβ3.

CONCLUSION:

Psychological stress disrupted embryo implantation by activating the GC/GR signaling. Tan IIA effectively alleviated stress-induced implantation disorders by inhibiting the GC/GR signaling. This study highlights the therapeutic potential of Tan IIA as a promising candidate for stress-related implantation disorders.

01 Jun 2025·LANCET

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Article

Author: Colombo, Nicoletta ; Diakos, Connie ; Artioli, Grazia ; McCollum, Michael E ; Hopp, Elizabeth ; Garbaos, Gabriel ; Van Gorp, Toon ; De La Cueva, Helena ; Mileshkin, Linda ; Oaknin, Ana ; Monk, Bradley J ; Scandurra, Giuseppa ; Balázs, Boglárka ; Salutari, Vanda ; Kang, Sokbom ; Leiser, Aliza L ; Scaranti, Mariana ; Pai, Sachin G ; Slomovitz, Brian ; Devaux, Alix ; Cassani, Chiara ; Gladieff, Laurence ; Lee, Yong Jae ; O'Malley, David M ; Bagaméri, Andrea ; Vergote, Ignace ; Kaczmarek, Emilie ; Bodnar, Lubomir ; Kesner-Hays, Amanda ; You, Benoit ; Caruso, Giuseppe ; Churruca, Cristina ; de Carvalho Calabrich, Aknar Freire ; Jubb, Adrian M ; Lorusso, Domenica ; Kim, Jae-Weon ; Nicum, Shibani ; McClung, Emily ; Clamp, Andrew ; Olawaiye, Alexander B ; Gilbert, Lucy ; Pashova, Hristina I ; Tudor, Iulia Cristina ; Kim, Byoung-Gie

BACKGROUND:

Relacorilant, a first-in-class selective glucocorticoid receptor antagonist, increases a tumour's sensitivity to chemotherapy by reducing cortisol signalling. This study aimed to show whether the addition of relacorilant to nab-paclitaxel improves progression-free and overall survival in females with platinum-resistant ovarian cancer.

METHODS:

This randomised, controlled, open-label phase 3 trial (ROSELLA [GOG-3073/ENGOT-ov72]) was done at 117 hospitals and community oncology treatment centres in 14 countries across Australia, Europe, Latin America, North America, and South Korea. Patients had to be aged 18 years or older and had to have a confirmed diagnosis of platinum-resistant, epithelial (ie, high-grade serous, endometrioid, or carcinosarcoma with a ≥30% epithelial component) ovarian, primary peritoneal, or fallopian tube cancer; up to three previous lines of anticancer therapy and previous bevacizumab and disease progression or intolerance to the most recent therapy; measurable disease according to the Response Evaluation Criteria in Solid Tumours (RECIST; version 1.1); an Eastern Cooperative Oncology Group performance status of 0 or 1; and adequate organ function. Patients were assigned (1:1) to relacorilant (150 mg orally the day before, of, and after nab-paclitaxel infusion) plus nab-paclitaxel (80 mg/m² intravenously on days 1, 8, and 15 of each 28-day cycle) or nab-paclitaxel monotherapy (100 mg/m² intravenously on the aforementioned schedule). The dual primary endpoints were progression-free survival assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumours (version 1.1) and overall survival, and were assessed in all randomly assigned patients by intention to treat. The safety population included all randomly assigned patients who received at least one dose of the assigned treatment. This trial was registered at ClinicalTrials.gov, NCT05257408, and is ongoing.

FINDINGS:

Between Jan 5, 2023, and April 8, 2024, 381 patients were randomly assigned to the combination group (n=188) or to the nab-paclitaxel monotherapy group (n=193). Patients receiving relacorilant plus nab-paclitaxel had a statistically significant improvement in progression-free survival assessed by blinded independent central review compared with those receiving nab-paclitaxel monotherapy (hazard ratio 0·70 [95% CI 0·54-0·91]; median 6·54 months [95% CI 5·55-7·43] vs 5·52 months [3·94-5·88]; stratified log-rank p=0·0076). At the planned interim analysis, there was a clinically meaningful difference in overall survival with the addition of relacorilant to nab-paclitaxel (0·69 [95% CI 0·52-0·92]; 15·97 months [95% CI 13·47-not reached] vs 11·50 months [10·02-13·57]; log-rank p=0·0121). Adverse events were similar across study groups when adjusted for nab-paclitaxel exposure; no new safety signals were observed.

INTERPRETATION:

The addition of relacorilant to nab-paclitaxel prolonged progression-free survival and interim results also showed an improvement in overall survival. Together, the results position the combination of relacorilant and nab-paclitaxel as a potential new standard treatment for patients with platinum-resistant ovarian cancer.

FUNDING:

Corcept Therapeutics.

News (Medical) associated with Relacorilant

02 Jan 2026

·www.fiercebiotech.com

Sanofi, Corcept surprised by FDA rejections for MS, Cushing\'s syndrome drugs

Corcept Therapeutics\' stock lost half its value in the wake of the FDA\'s decision.\n The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the companies’ respective drug applications.Sanofi revealed Dec. 24 that the FDA had knocked back its approval submission for tolebrutinib in non-relapsing secondary progressive multiple sclerosis (nrSPMS). The agency’s decision will have come as an especially nasty shock for the French pharma, which only weeks earlier had been told by the FDA that the approval decision would no longer be made in time for a previously confirmed Dec. 28 deadline.In secondary progressive MS, patients typically have been diagnosed with relapsing MS but have stopped having relapses and instead experience so-called “disability accumulation.” Despite advances in MS care, unmet need remains in this treatment setting as options are limited, according to the company.Back in March, Sanofi picked up an FDA priority review for the nrSPMS filing and touted an expected approval decision by Sept. 28. But, as that date neared in the fall, the drugmaker disclosed a three-month delay due to its submission of “additional analyses” during the review, which constituted a major amendment to the application by the FDA\'s standards.With the amended deadline nearing, Sanofi then announced Dec. 15 that it had been warned by the FDA not to expect any new guidance for the application until March 2026.With a decision no longer expected anytime soon, it means that the CRL last week marked a “significant and meaningful change in direction from the feedback the agency previously provided to Sanofi,” the pharma’s head of R&D Houman Ashrafian, Ph.D., said in a Dec. 24 statement. “We are very disappointed by the FDA\'s action,” Ashrafian continued. “Disability progression remains a large unmet medical need in MS, and tolebrutinib was previously awarded breakthrough therapy designation by the FDA in recognition of its potential to address this critical gap.”“We believe that the FDA should also take the advice of scientific experts, clinicians, and patients in this matter to ensure all perspectives are considered,” he added. “We remain committed to working with the FDA to find a path forward for tolebrutinib and ultimately serve the MS community.”Sanofi didn’t elaborate further on the FDA’s rationale behind its change of heart.The rejection is only the latest in a string of setbacks for tolebrutinib, which Sanofi acquired as part of its $3.7 billion buyout of Principia Biopharma back in 2021. The following year, the FDA put a group of late-stage studies under a partial clinical hold so it could review reports of drug-induced liver injury.Then, in 2023, Sanofi reported that the drug failed two out of three late-stage studies in MS but that it still planned to seek an approval in nrSPMS thanks to its clinical win in that indication. The mixed bag of results ultimately dented the med\'s therapeutic scope, and Sanofi removed tolebrutinib\'s use in relapsing MS from its pipeline early this year.The company only recently disclosed that the phase 3 Perseus study missed the mark in patients with primary progressive MS, leading Sanofi to decide against seeking regulatory approval in that specific indication as well. Corcept \"surprised and disappointed\" The CRL that landed in Corcept’s post box over the holidays will have been an equally unwelcome surprise. The company had submitted its approval application for its lead asset relacorilant on the back of a phase 3 win last year for the antiglucocorticoid in the Grace study of patients with Cushing’s syndrome.According to Corcept, the FDA “acknowledged that Corcept’s pivotal Grace trial met its primary endpoint and that data from the company’s Gradient trial provided confirmatory evidence.”However, the agency “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness,” the biotech explained in a Dec. 31 release. Corcept CEO Joseph Belanoff, M.D., said the company was “surprised and disappointed by this outcome.”“I am confident we will find a way to get relacorilant to the patients it could help,” Belanoff added. “We will meet with the FDA as soon as possible to discuss the best path forward.”Investors didn’t appear reassured, wiping 50% of the value of the company’s stock so it ended Thursday’s trading on $34.80 compared to a Wednesday closing price of $70.20.The FDA has penciled in a July 2026 decision date for a separate approval application from Corcept for relacorilant in platinum-resistant ovarian cancer.

$Sanofi, Corcept surprised by FDA rejections for MS, Cushing\'s syndrome drugs$

Phase 3Breakthrough TherapyPriority ReviewAccelerated Approval

02 Jan 2026

·www.biospace.com

FDA Rejects Corcept and Outlook Filings, Crushing Stock Prices

iStock/ Naypong Both companies received agency requests for more evidence of the effectiveness of their therapies. The FDA closed out 2025 with a pair of complete response letters, cratering the share prices of Corcept Therapeutics and Outlook Therapeutics. Both companies reported that the agency had rejected a request for approval on Dec. 31. Corcept was seeking authorization of relacorilant in patients with high blood pressure secondary to hypercortisolism, a rare condition also called Cushing’s syndrome that is caused by too much cortisol. Outlook had applied for approval of a formulation of bevacizumab in wet age-related macular degeneration (AMD). Corcept sought FDA approval despite finding relacorilant was statistically no better than placebo in one of two Phase III trials. The FDA acknowledged that one trial met its primary endpoint and that the failed study provided confirmatory evidence, according to Corcept. Yet the FDA concluded Corcept needs more evidence of effectiveness to show that relacorilant, an oral selective glucocorticoid receptor antagonist, has a favorable benefit-risk pro the patient population. Truist Securities analysts wrote in a note to investors that the request for additional data “may require additional trial(s), significantly dimming [Corcept’s] outlook in Cushing’s.” Corcept CEO Joseph Belanoff said in a statement that he is “confident we will find a way to get relacorilant to the patients it could help,” adding that the biotech plans to meet with the FDA as soon as possible. Truist analysts said it is unclear if any dialogue can resolve the issues without one or more new trials, given that Corcept had chances to address the FDA’s concerns during the original review. Shares in Corcept fell 50% to $34.80 at close on December 31 following the FDA rejection. The analysts cut their price target from $135 to $50. Corcept has a chance to regain momentum when the FDA rules on relacorilant in ovarian cancer. The analysts said the Cushing’s rejection has no bearing on the ongoing FDA review, which is to conclude by July 11. Outlook shared details of its FDA rejection after the market closed on Dec. 31. The stock fell 61% to 62 cents in premarket trading on Jan. 2. The setback was the third time the FDA has rejected a request for approval of Outlook’s ophthalmic formulation of bevacizumab in wet AMD. Roche developed Avastin as a cancer drug, but physicians have used the anti-VEGF antibody off-label in eye diseases including wet AMD. The FDA rejected Outlook’s second approval request in August over a lack of substantial evidence of effectiveness. Outlook included additional mechanistic and natural history data in its resubmission, but the FDA again rejected the application and asked for confirmatory evidence of efficacy. The biotech said its submission included data from a pivotal trial and confirmatory evidence from other studies. Outlook CEO Bob Jahr said in a statement that the company remains “fully committed to taking all necessary steps to receive approval in the United States.” The company is now exploring all available pathways for potential approval. Outlook has already won approval in Europe, where it sells the drug as Lytenava. The rejections came one week after the FDA issued a complete response letter for Sanofi’s multiple sclerosis drug candidate tolebrutinib. Houman Ashrafian, head of R&D at Sanofi, said in a statement that the FDA’s decision “is a significant and meaningful change in direction from the feedback the agency previously provided.”

Phase 3Clinical ResultDrug ApprovalAccelerated Approval

31 Dec 2025

·www.businesswire.com

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA or the Agency) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism. While the FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the company’s GRADIENT trial provided confirmatory evidence, the Agency concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness. “We are surprised and disappointed by this outcome,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. “Our commitment to patients suffering from the effects of hypercortisolism is unwavering. I am confident we will find a way to get relacorilant to the patients it could help. We will meet with the FDA as soon as possible to discuss the best path forward.” About Relacorilant Relacorilant, an oral therapy, is a selective glucocorticoid receptor (GR) antagonist that modulates cortisol activity by binding to the GR but not to the body's other hormone receptors. Corcept is developing relacorilant in endogenous hypercortisolism and a variety of other serious disorders, including ovarian cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. It has been designated an orphan drug by the FDA and the European Commission (EC) for the treatment of hypercortisolism and by the EC for the treatment of ovarian cancer. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026 for relacorilant as a treatment for patients with platinum-resistant ovarian cancer. Corcept also recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for relacorilant to treat patients with platinum-resistant ovarian cancer. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders, leading to the discovery of more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com. Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations and are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties are set forth in our SEC filings, which are available at our website and the SEC’s website. In this press release, forward-looking statements include statements concerning: the clinical data concerning the safety and efficacy of relacorilant, including the results of our GRACE and GRADIENT trials; our plans to meet with the FDA as soon as possible; and any new clinical data, analyses or regulatory processes that may be required for relacorilant to receive approval as a treatment for patients with endogenous hypercortisolism or any other indication. We disclaim any intention or duty to update forward-looking statements made in this press release.

Orphan DrugDrug ApprovalNDA

100 Deals associated with Relacorilant

External Link

KEGG	Wiki	ATC	Drug Bank
D11336	Relacorilant	-	DB14976

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Platinum-Resistant Ovarian Carcinoma	NDA/BLA	United States	Corcept Therapeutics, Inc.	14 Jul 2025
Cushing Syndrome	NDA/BLA	United States	Corcept Therapeutics, Inc.	30 Dec 2024
Ovarian Cancer	Phase 3	United States	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	United States	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Argentina	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Australia	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Belgium	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Brazil	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Canada	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	France	Corcept Therapeutics, Inc.	29 Jun 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04308590 (GRADIENT, CTgov)	Phase 3	Cushing Syndrome \| Adrenocortical Adenoma	137	Placebo+Relacorilant (Relacorilant)	vcxuyzaauu(xmafuyjrna) = ckysouvwuv zldhzbyssf (kwvxuajcmd, wxwcltfhvm - knlfayrnvm) View more	-	03 Aug 2025
				Placebo (Placebo)	vcxuyzaauu(xmafuyjrna) = xjvjnjaldj zldhzbyssf (kwvxuajcmd, ugkcopwuch - yptunphnjv) View more
NCT05257408 (ROSELLA \| GOG-3073 \| ENGOT-ov72, ESMO_GCC2025)	Phase 3	Platinum-Resistant Ovarian Carcinoma	381	Relacorilant + nab-paclitaxel	sweauepuzy(zexhipfvbp) = clbxtjpnfy yhbcifoguc (ikvcsimngg ) View more	Positive	19 Jun 2025
				nab-paclitaxel	sweauepuzy(zexhipfvbp) = ijlzfcfwtk yhbcifoguc (ikvcsimngg ) View more
NCT03776812 (CTgov)	Phase 2	Recurrent Platinum-Resistant Primary Peritoneal Carcinoma \| Recurrent ovarian cancer \| Recurrent Primary Peritoneal Carcinoma ... View more	178	Nab-paclitaxel+Relacorilant (Arm A: Continuous Relacorilant Dosing)	spilabtsso(gvrswfpszk) = bmuhqoinhq akybfvcdxc (nmzpqdscfd, ehfrarkcwq - mmlgcsjoqs) View more	-	30 Apr 2025
				Nab-paclitaxel+Relacorilant (Arm B: Intermittent Relacorilant Dosing)	spilabtsso(gvrswfpszk) = vuyoqocpnw akybfvcdxc (nmzpqdscfd, sjxiacrqwa - lralamdvnr) View more
NCT03697109 (GRACE, CTgov)	Phase 3	Endogenous Cushing Syndrome	152	Relacorilant (Relacorilant (RW Phase))	azjayhrwlr = yiromhepcw hlrxkxttys (vigufebmmk, acemxtkyyf - xwqfqtxoes) View more	-	24 Apr 2025
				Placebo (Placebo (RW Phase))	azjayhrwlr = mmnjksagmu hlrxkxttys (vigufebmmk, njvwdygzts - yjddbjgqwj) View more
NCT05257408 (ROSELLA, Company_Website \| NEWS) Manual	Phase 3	Platinum-Resistant Ovarian Carcinoma	381	Relacorilant + nab-paclitaxel	rqvrrjwvtu(htzujnxazf) = qfrgogqgtz vtrsznehok (iaimigeivv, 5.55 - 7.43) Met View more	Positive	31 Mar 2025
				Nab-paclitaxel	rqvrrjwvtu(htzujnxazf) = ybjsgqwgyj vtrsznehok (iaimigeivv, 3.94 - 5.88) Met View more
NCT03604198 (BusinessWire) Manual	Phase 3	Cushing Syndrome	116	Relacorilant	xgikmdqtgr(stabzvxoex) = At month 24 of the study, patients exhibited clinically meaningful and statistically significant reductions in mean systolic blood pressure (10.0 mm Hg; p-value: 0.012) and mean diastolic blood pressure (7.3 mm Hg; p-value: 0.016), compared to their measurement at entry into the long-term extension study. pikkrfkiad (laegoxqdyc ) View more	Positive	16 Dec 2024
NCT03604198 (Company_Website) Manual	Phase 2	Cushing Syndrome	53	Relacorilant	sjpatoegmt(cmssxbydly) = izfulcgqbg fkrpnjjlyh (awfddqdqum ) View more	Positive	25 Nov 2024
NCT04308590 (GRADIENT, Biospace) Manual	Phase 3	Cushing Syndrome	137	relacorilant	fceoxiwjbg(fgcvvqcscq) = ptdfjzjcmz exfujddhlk (lstedsujpu ) Met	Positive	30 Oct 2024
				Placebo	fceoxiwjbg(fgcvvqcscq) = nivwpjjvpm exfujddhlk (lstedsujpu ) Met
NCT02804750 \| NCT00280475 (Pubmed \| J Endocrinol Invest)	Phase 2	Cushing Syndrome factor VIII \| activated partial thromboplastin time \| platelet count ... View more	34	Relacorilant (Surgery)	njfdatuytd(vimecynflw) = vrpxnbmcjz xypymzccpk (nfssdyzncw )	Positive	21 Sep 2024
NCT03697109 (GRACE, ENDO2024)	Phase 3	Cushing Syndrome	152	Relacorilant 100 mg QD	nodnykyayg(wtttmpiesv) = tbvsajxwkk chbnxmhcxu (sotafiqqfi, 6.7) View more	Positive	01 Jun 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis